Polypharmacy in multiple sclerosis.
The goal of this article is to describe therapeutic approaches to multiple sclerosis (MS) which may be applicable to other human conditions such as epilepsy. Polypharmacy is very commonly employed in MS and it is likely to increase in the future. This paper is written with the premise that therapeutic principles and practices underlying the care of patients with MS may be useful for the treatment of people with epilepsy. We will point out some of the analogies between MS and epilepsy and we will describe the polypharmacy approach employed to treat patients with MS. We will review current information as to the etiology and pathogenesis of MS and describe potential therapeutic targets derived from this knowledge. We will identify or suggest certain therapeutic principles underlying polypharmacy in MS which may be relevant to epilepsy or other conditions. Finally, we will describe some of the obstacles to expanding rational polypharmacy and how we might overcome these problems.
Myers
L W
LW
Department of Neurology, UCLA School of Medicine, USA. 1LU0LWM@MVS.OAC.UCLA.edu
Phillips
J T
JT
D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002491:Central Nervous System Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003198:Computer Simulation; D016207:Cytokines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008959:Models, Neurological; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010166:Palliative Care
D002491:Central Nervous System Agents; D016207:Cytokines; D007166:Immunosuppressive Agents